A carregar...
Everolimus and Malignancy after Solid Organ Transplantation: A Clinical Update
Malignancy after solid organ transplantation remains a major cause of posttransplant mortality. The mammalian target of rapamycin (mTOR) inhibitor class of immunosuppressants exerts various antioncogenic effects, and the mTOR inhibitor everolimus is licensed for the treatment of several solid cancer...
Na minha lista:
| Publicado no: | J Transplant |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Hindawi Publishing Corporation
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5078653/ https://ncbi.nlm.nih.gov/pubmed/27807479 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2016/4369574 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|